Dublin, March 14, 2017 -- Research and Markets has announced the addition of the "Compliance Risk Management in Medical Devices, Pharmaceuticals, and Combination Products" conference to their offering.
Effective risk management is the hallmark of a successful corporation. Increasingly, it is also the hallmark of a compliant corporation. While Medical Devices, Pharmaceuticals, and Combination Products have had unique histories for the evolution of risk management, the management of compliance risk is a common business process for all three areas.
Enterprise Risk Management (ERM) is the generic term for managing the risks of an organization. ISO 31000 is the ERM ISO Standard. This standard provides guidance for organizations on implementing ERM solutions. ISO 9001 is the Quality Systeme Standard. ISO 9001 now requires to establish risk-based thinking. As a result, ISO 13485, the International Quality System Standard for Medical Devices, has been revised to include requirements for firms to implement Compliance Risk Management. These requirements are in addition to the requirements as currently defined by ISO 14971, the International Standard for Risk Management of Medical Devices.
What is the difference between Compliance Risk Management and Product Risk Management? What about acceptability criteria for Compliance Risk Management? Should we merge the Compliance Risk Management activities into the existing Risk Management for Products? What are the expectations for managing risk in Pharmaceuticals (cGMP)? How does the evolving landscape of Compliance Risk Management interface with the evolving landscape of Combination Products?
In this one and a half day workshop, you will learn how to implement effective Compliance Risk Management in your organization. It is important that key personnel understand what a successful implementation of both ERM and Product Risk Management (ISO 14971) looks like. There are existing tools that may be adapted to implement the new requirements efficiently.
Learning Objectives:
- Read and understand what the expectations are for manufacturers of Medical Devices, Pharmaceuticals, and Combination Products that will be regulated by ISO 13485.
- Understand how to utilize a risk-based approach to addressing Compliance Risk Management requirements.
- Evaluate the effectiveness of Risk Management for Compliance and Product (ISO 14971)
- Develop appropriate Acceptability Criteria for Product and Compliance Risk Management
- Discriminate between the expectations of Medical Devices, Pharmaceuticals, and Combination Products
- Implement new or revised tools for improving Risk Management outcomes, both audit and field performance
Who will Benefit:
- Senior quality managers
- Quality professionals
- Regulatory professionals
- Compliance professionals
- Production managers
- Manufacturing engineers
- Production engineers
- Design engineers and managers
- Process owners
- Quality engineers
- Quality auditors
- Document control specialists
For more information about this conference visit http://www.researchandmarkets.com/research/nv6vgj/compliance_risk
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Medical Devices


Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 



